No Data
No Data
The Supreme Court of Delaware will review the cancer-causing evidence of glaxosmithkline (GSK.US)'s Zantac.
The Supreme Court of Delaware will review a previous ruling by a lower court that allowed the evidence submitted by the plaintiff to be heard in the upcoming trial.
Analyst Issues Sell Rating for GlaxoSmithKline Amid Legal Challenges and Financial Risks
GSK Committed to Defending Itself, Managing This Litigation
GSK's Nucala (Mepolizumab) Approved in Japan for Treatment of Adults With Chronic Rhinosinusitis With Nasal Polyps
GSK Shares Rise as Delaware's Top Court to Review Allowing Expert Testimony in Zantac Trial
Express News | GSK Statement On Zantac (Ranitidine) Litigation; Delaware Supreme Court To Review Superior Court's Daubert Decision
No Data